MetaVia (MTVA) EBITDA Margin: History & Chart

MetaVia Inc.(MTVA)

Biotechnology · Cambridge, MA

$1.50-0.04 (-2.60%)

Delayed quote: Oct 6, 2026, 2:18 PM EDT

About MetaVia Inc.

Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.

Cambridge, MA

8 employees

www.metaviatx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Hyung Heon Kim

View full financials

NAME	MARKET CAP	EBITDA MARGIN	TTM	3Y	5Y
MetaVia Inc. (MTVA)	$9.88M	N/A	N/A	N/A	N/A
NeuroOne Medical Technologies Corporation (NMTC)vs ›	$9.57M	-32.77%	-184.94%	-1690.71%	-2111.15%
Ainos, Inc. (AIMD)vs ›	$9.68M	-7418.23%	-25513.08%	-14528.12%	-11171.17%
Medicus Pharma Ltd. Common Stock (MDCX)vs ›	$10.09M	N/A	N/A	N/A	N/A
Valion Bio, Inc. (VBIO)vs ›	$10.11M	-685.63%	-612.49%	-514.11%	-584.57%
SeaStar Medical Holding Corporation (ICU)vs ›	$9.31M	-985.17%	-7100.73%	-7100.73%	-7100.73%
Advanced Biomed Inc. Common Stock (ADVB)vs ›	$9.29M	N/A	N/A	N/A	N/A
Lifeward Ltd. (LFWD)vs ›	$10.65M	-75.15%	-68.19%	-159.10%	-185.14%
Satellos Bioscience Inc. (MSLE)vs ›	$10.38M	-2995.72%	-2995.72%	-2995.72%	-2995.72%
Polyrizon Ltd. (PLRZ)vs ›	$10.37M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EBITDA MARGIN

TTM

MetaVia Inc. (MTVA)

$9.88M

N/A

NeuroOne Medical Technologies Corporation (NMTC)vs ›

$9.57M

-32.77%

-184.94%

-1690.71%